Mirum Pharmaceuticals has raised $75m in its initial public offering that had an initial target of $86.3m and provided exits to Novo and Shire.
GlaxoSmithKline, Sanofi and 6 Dimensions Capital have all secured exits as the rare disease treatment developer raised $72m in its initial public offering.
Tencent-backed Douyu has successfully listed on Nasdaq after completing a $775m initial public offering that came after economic tensions forced a delay earlier this year.
IndiaMart, backed by Intel Capital and Brand Equity Treaty, has listed on the National Stock Exchange after raising $69m in its initial public offering.
PureTech Health spinoff Karuna Therapeutics has upscaled its IPO to nearly $103m, after its shares rose by more than 50% in its first days of trading.
The corporate-backed small molecule therapeutic developer has boosted its initial public offering from $90m to nearly $104m.
PureTech Health-backed neuropsychiatric drug developer Karuna Therapeutics raised $89.2m in an upsized offering that followed $123m in venture capital.
AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
Shares in Adaptive Biotechnologies, backed by Microsoft, Celgene, Illumina, LabCorp and BD Biosciences, soared more than 100% on its first day of trading.
Novel Group-backed luxury goods marketplace The RealReal will raise $300m in an initial public offering in which it will float above its range.